Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

Sanofi (EURONEXT: SAN and NASDAQ: SNY) and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce today a collaboration to co-develop and co-commercialize asset TEV’574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, two types of inflammatory bowel disease.

Artiva’s IPO raises $167M to fund company’s autoimmune and cancer cell therapies

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 20, 2024

‘The more overhype, the harder you fall’: Schrödinger CEO warns on AI craze

When sell-side analyst Evan Seigerman was preparing to start covering the startup Schrödinger this spring, he rang up the $3.5 billion biotech’s chief financial officer,

July 6, 2023

Pharmalittle: We’re reading about a GSK deal, a probe into inhaler prices, and more

Rise and shine, everyone, another busy day is on the way. We can tell by the number of dispatches being filed from the J.P. Morgan

January 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.